ArtsAutosBooksBusinessEducationEntertainmentFamilyFashionFoodGamesGenderHealthHolidaysHomeHubPagesPersonal FinancePetsPoliticsReligionSportsTechnologyTravel

Benlysta -1st Drug to Treat Lupus

Updated on June 24, 2021

Lupus Foundation

source National Lupus Foundation Sign
source National Lupus Foundation Sign

A Drug to Specifically Treat Lupus

November 20, 2008, marked the fiftieth year without any medication to actually treat the disease of Systemic Lupus. Clinical describes systemic lupus erythematosus on their website. On November 18th, the FDA approved the sale of Benlysta (Belimumab) to the public and announced this decision on December 9, 2010. Lupus patients had waited a long time for such a drug. Previously patients had been treated with many other harsh medications to suppress the immune system.

I started taking Benestyl Intravenous medication in December and by my third dose I had less joint pain. The drug regimen is as follows: 1 dose every other week times three, then a dose every four weeks. I will be getting my fourth dose in a little over a week and I have great hopes that I will continue to improve and that I will be able to wean off the Prednisone.

S.L.E. Lupus Foundation: Life Without Lupus

Auto-immune Disease

SLE is an often crippling and potentially fatal autoimmune disease that is nine times more prevalent in women than in men. It is four times more likely to affect African American females than Caucasian females. It is suspected that a genetic predisposition along with environmental factors contribute to the clinical manifestation of SLE, but it is not considered to be an inherited disease.

This positive note reinforces our community’s resolve to increase the pace of scientific discovery and clinical development for lupus patients that is made possible by the active participation of lupus patients in clinical trials,

Butterfly Rash

source medicalsymptomsguide
source medicalsymptomsguide

Medical Studies

The new medical studies for Lupus are very exciting as they are actually developing medication that treats the disease rather than just the symptoms.

Medical studies are typically double blind studies so you don’t know if you are receiving the medicine or the placebo. You must also meet the specific criteria for any given study to qualify for their study. Typically these programs accept both genders, patients between 18-70, must have had stable SLE for a duration of at least 6 months and you must sign a written informed consent.

A great deal of lab work is done during the first interview, which includes an ANA screen, HIV test, Hepatitis screen and an EKG. You will be excluded if you have HIV, hepatitis B or C, have had a viral, bacterial or fungal infection within 30 days; have donated blood or experienced a loss of blood >500mL within 4 weeks of randomization or have evidence of renal insufficiency

Other disqualifications: renal glomerular filtration rate <50, total WBC <3000, Neutrophil count <1500, Platelet count <75,000, Hemoglobin <10g/dl, and there is a whole list of other comorbidities that would disqualify you.

FDA Advisory Committee's Recommendation to Approve Benlysta

Lupus Difficult to Diagnose

Lupus is typically diagnosed by symptoms and some lab work but there is no specific test for lupus. The more common symptoms are:

  • Extreme Fatigue
  • Painful and sometimes swollen joints
  • Anemia with low RBCs and'or Platelets
  • Low grade Fever
  • Pleurisy - Pain in the chest when taking a deep breath
  • Hair loss
  • Rashes, 15% have a butterfly rash which runs across the cheeks and nose
  • Sun sensitivity or light sensitivity
  • Abnormal blood clotting
  • Swelling (edema) in feet, legs, hands and/or around eyes
  • Mouth or nose ulcers
  • Kidney disease
  • Fingers that turn white and/or blue when exposed to cold (Raynaud's syndrome)

In Summary

Benlysta or BLISS-76 has been on the market for over a year. The results have been a Godsend for many lupus patients. I will include their webpage if you would like to read about this medication as the way it functions is a bit too complex for this article.

Belimumab was developed by HGS and GlaxoSmithKline. They completed enrollment for Phase 3 starting in the fall of 2009. The results were again positive, so it will be available on the market in the first part of 2011.

There is a tremendous amount of lupus research happening at the time. The Lupus Foundation of America describes some of the research they are involved with and they have a wealth of information about the disease. If you or a loved one has lupus, please stay informed and learn everything you can to help cope with this disease in your daily life.

This content is accurate and true to the best of the author’s knowledge and does not substitute for diagnosis, prognosis, treatment, prescription, and/or dietary advice from a licensed health professional. Drugs, supplements, and natural remedies may have dangerous side effects. If pregnant or nursing, consult with a qualified provider on an individual basis. Seek immediate help if you are experiencing a medical emergency.


This website uses cookies

As a user in the EEA, your approval is needed on a few things. To provide a better website experience, uses cookies (and other similar technologies) and may collect, process, and share personal data. Please choose which areas of our service you consent to our doing so.

For more information on managing or withdrawing consents and how we handle data, visit our Privacy Policy at:

Show Details
HubPages Device IDThis is used to identify particular browsers or devices when the access the service, and is used for security reasons.
LoginThis is necessary to sign in to the HubPages Service.
Google RecaptchaThis is used to prevent bots and spam. (Privacy Policy)
AkismetThis is used to detect comment spam. (Privacy Policy)
HubPages Google AnalyticsThis is used to provide data on traffic to our website, all personally identifyable data is anonymized. (Privacy Policy)
HubPages Traffic PixelThis is used to collect data on traffic to articles and other pages on our site. Unless you are signed in to a HubPages account, all personally identifiable information is anonymized.
Amazon Web ServicesThis is a cloud services platform that we used to host our service. (Privacy Policy)
CloudflareThis is a cloud CDN service that we use to efficiently deliver files required for our service to operate such as javascript, cascading style sheets, images, and videos. (Privacy Policy)
Google Hosted LibrariesJavascript software libraries such as jQuery are loaded at endpoints on the or domains, for performance and efficiency reasons. (Privacy Policy)
Google Custom SearchThis is feature allows you to search the site. (Privacy Policy)
Google MapsSome articles have Google Maps embedded in them. (Privacy Policy)
Google ChartsThis is used to display charts and graphs on articles and the author center. (Privacy Policy)
Google AdSense Host APIThis service allows you to sign up for or associate a Google AdSense account with HubPages, so that you can earn money from ads on your articles. No data is shared unless you engage with this feature. (Privacy Policy)
Google YouTubeSome articles have YouTube videos embedded in them. (Privacy Policy)
VimeoSome articles have Vimeo videos embedded in them. (Privacy Policy)
PaypalThis is used for a registered author who enrolls in the HubPages Earnings program and requests to be paid via PayPal. No data is shared with Paypal unless you engage with this feature. (Privacy Policy)
Facebook LoginYou can use this to streamline signing up for, or signing in to your Hubpages account. No data is shared with Facebook unless you engage with this feature. (Privacy Policy)
MavenThis supports the Maven widget and search functionality. (Privacy Policy)
Google AdSenseThis is an ad network. (Privacy Policy)
Google DoubleClickGoogle provides ad serving technology and runs an ad network. (Privacy Policy)
Index ExchangeThis is an ad network. (Privacy Policy)
SovrnThis is an ad network. (Privacy Policy)
Facebook AdsThis is an ad network. (Privacy Policy)
Amazon Unified Ad MarketplaceThis is an ad network. (Privacy Policy)
AppNexusThis is an ad network. (Privacy Policy)
OpenxThis is an ad network. (Privacy Policy)
Rubicon ProjectThis is an ad network. (Privacy Policy)
TripleLiftThis is an ad network. (Privacy Policy)
Say MediaWe partner with Say Media to deliver ad campaigns on our sites. (Privacy Policy)
Remarketing PixelsWe may use remarketing pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to advertise the HubPages Service to people that have visited our sites.
Conversion Tracking PixelsWe may use conversion tracking pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to identify when an advertisement has successfully resulted in the desired action, such as signing up for the HubPages Service or publishing an article on the HubPages Service.
Author Google AnalyticsThis is used to provide traffic data and reports to the authors of articles on the HubPages Service. (Privacy Policy)
ComscoreComScore is a media measurement and analytics company providing marketing data and analytics to enterprises, media and advertising agencies, and publishers. Non-consent will result in ComScore only processing obfuscated personal data. (Privacy Policy)
Amazon Tracking PixelSome articles display amazon products as part of the Amazon Affiliate program, this pixel provides traffic statistics for those products (Privacy Policy)
ClickscoThis is a data management platform studying reader behavior (Privacy Policy)